Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.57 |
| ▸ | CA2 | P00918 | 10/20 | 0.57 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 8/20 | 0.39 |
| ▸ | CA9 | Q16790 | 8/20 | 0.39 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 5/20 | 0.35 |
| ▸ | CA7 | P43166 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3759241 | 0.98 | CA1 (0.55) | CA1CA2IKBKBCHUKHPGD | |
| SCHEMBL3763304 | 0.80 | CA1 (0.54) | CA1CA2IKBKBCHUKHPGD | |
| Hydrochloric Acid SCHEMBL21633570 | 0.78 | CA1 (0.52) | CA1CA2IKBKBCHUKHPGD | |
| SCHEMBL9762891 | 0.78 | HPGD (0.59) | CA1CA2HPGDLMNAHTT | |
| SCHEMBL980565 | 0.78 | CA1 (0.48) | CA1CA2HPGDLMNAHTT | |
| SCHEMBL981469 | 0.78 | HPGD (0.64) | CA1CA2HPGDLMNAHTT | |
| SCHEMBL23693483 | 0.77 | LMNA (0.47) | CA1CA2IKBKBCHUKLMNA | |
| SCHEMBL6402087 | 0.77 | CA1 (0.61) | CA1CA2HPGDLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21633755 | 0.75 | KIF11 (0.59) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6665659 | 0.72 | CA1 (0.50) | CA1CA2HPGDLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238119-B1 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2015-11-25 | — | — | EP | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-8530486-B2 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2013-09-10 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | VERENIGING VOOR CHRISTELIJK, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG (NL) | 2010-11-25 | — | — | US | disclosed |
| EP-2077263-A1 | Quinazolines and related heterocyclic compounds and their therapeutic use | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg (NL) | 2009-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298322-A1 | Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use | RXFP3, RXFP1, NR1I3 | CA1 1433/4885CA2 879/4885IKBKB 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.